Amylyx Pharmaceuticals, Inc. (AMLX)

NMS – Real vaqt narxi. Valyuta: USD

14.44

-0.44 (-2.96%)

Yopilishda: May 12, 2026, 4:00 PM EDT

14.55

+0.11 (0.76%)

Bozor oldidan: May 13, 2026, 4:44 AM EDT

07.05.2026

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript

07.05.2026

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results.

06.05.2026

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences.

05.05.2026

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the launch of a U.S. Expanded Access Program (EAP) for up to 250 adults with post-bariatric hypoglycemia (PBH) to provide treatment access to avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. The EAP allows U.S. physicians to request avexitide for adults with PBH following Roux-en-Y gastric bypass (RYGB) surgery who have a se.

30.04.2026

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026.

09.04.2026

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

08.04.2026

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference.

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results.

05.05.2026

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

09.04.2026

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

24.03.2026

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia.

Amylyx Pharmaceuticals, Inc. (AMLX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Amylyx Pharmaceuticals, Inc. (AMLX)

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

Videolar

No Data

Press-relizlar

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

Videolar

No Data

Press-relizlar

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

Search stocks

Amylyx Pharmaceuticals, Inc. (AMLX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Amylyx Pharmaceuticals, Inc. (AMLX)

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

Videolar

No Data

Press-relizlar

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

Videolar

No Data

Press-relizlar

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia